OVERVIEW OF ACTIVITY
Today, numerous annual oncology conferences supported by various associations and organizations lead to the release of new clinical data, and hundreds of peer-reviewed publications feature articles related to cancer research, treatment and management. To bridge the gap between research and patient care, this web-based activity uses didactic presentations to apply evidence-based concepts in routine clinical care. The activity focuses on six different areas of oncology: breast cancer, gastrointestinal cancers, lung cancer, MDS/AML, NHL/CLL and multiple myeloma. These have been selected based on a number of factors including the overwhelming need for and interest of practicing oncologists in additional educational resources in these malignancies. By providing access to the latest research developments on the treatment of these significant tumor types in a single event, this activity will assist medical oncologists and hematologists in the formulation of up-to-date clinical management strategies.
TARGET AUDIENCE
This activity has been designed to meet the educational needs of medical, surgical and radiation oncologists and hematologists.
LEARNING OBJECTIVES
Upon completion of this activity, participants should be able to:
- Apply the results of emerging clinical trial data, including those presented at the 2009 ASCO annual meeting, to the evidence-based care of patients with breast, gastrointestinal, thoracic and hematologic cancers.
- Recall the design of ongoing trials in breast, gastrointestinal, thoracic and select types of hematologic cancer, and identify how they may impact existing treatment algorithms.
- Effectively integrate commercially available targeted monoclonal antibodies and tyrosine kinase inhibitors into the individualized management of common tumors.
- Summarize the findings from recent clinical trials designed to test the efficacy and safety of diverse combination chemotherapeutic and/or biologic approaches for patients with advanced-stage cancer.
- Utilize clinical risk factors, cytogenetics and other biomarkers to tailor therapy for patients with hematologic cancer.
- Counsel appropriately selected patients for participation in ongoing clinical trials evaluating novel agents and regimens for the treatment of cancer.
ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
Research To Practice designates this educational activity for a maximum of 2.75 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
HOW TO USE THIS CME ACTIVITY
This CME activity is a web-based video. To receive credit, the participant should review the Internet content and complete the Post-test and Educational Assessment and Credit Form located at
CME.ResearchToPractice.com.
CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
FACULTY — Dr Winer and Dr Wolff had no real or apparent conflicts of interest to disclose. The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr Kim — Advisory Committee: AstraZeneca Pharmaceuticals LP, Genentech BioOncology, ImClone Systems Incorporated, Lilly USA LLC, OSI Oncology, Sanofi-Aventis; Paid Research: AstraZeneca Pharmaceuticals LP, Genentech BioOncology, ImClone Systems Incorporated, Lilly USA LLC, OSI Oncology. Dr Ghobrial — Advisory Committee: Celgene Corporation, Novartis Pharmaceuticals Corporation; Speakers Bureau: Celgene Corporation, Millennium Pharmaceuticals Inc, Novartis Pharmaceuticals Corporation. Dr Kantarjian — Paid Research: Bristol-Myers Squibb Company, Genzyme Corporation, Novartis Pharmaceuticals Corporation. Dr Czuczman — Advisory Committee: Amgen Inc, Biogen Idec, Celgene Corporation, Cephalon Inc, Genentech BioOncology, GlaxoSmithKline, Lilly USA LLC, Millennium Pharmaceuticals Inc, Novartis Pharmaceuticals Corporation; Lectures: Biogen Idec, Genentech BioOncology.
MODERATOR — Neil Love: Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: Abraxis BioScience, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer Pharmaceuticals Corporation/Onyx Pharmaceuticals Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Centocor Ortho Biotech Services LLC, Cephalon Inc, Eisai Inc, EMD Serono Inc, Genentech BioOncology, Genomic Health Inc, Genzyme Corporation, GlaxoSmithKline, ImClone Systems Incorporated, Lilly USA LLC, Merck and Company Inc, Millennium Pharmaceuticals Inc, Monogram BioSciences Inc, Novartis Pharmaceuticals Corporation, OSI Oncology, Roche Laboratories Inc, Sanofi-Aventis and Wyeth.
RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.
This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
This program is supported by educational grants from AstraZeneca Pharmaceuticals LP, Celgene Corporation, Genentech BioOncology, Genomic Health Inc, Millennium Pharmaceuticals Inc and Sanofi-Aventis.
Hardware/Software Requirements:
An Internet connection that is at least 28.8 Kbps
A monitor set to 1280 x 1024 pixels or more
Netscape 7.x or newer, Internet Explorer 5.x or newer, or Firefox
Macromedia Flash plug-in 6.0 or greater
Adobe Acrobat Reader
(Optional) Sound card and speakers for audio
Last review date: December 2009
Expiration date: December 2010
OVERVIEW OF ACTIVITY
Today, numerous annual oncology conferences supported by various associations and organizations lead to the release of new clinical data, and hundreds of peer-reviewed publications feature articles related to cancer research, treatment and management. To bridge the gap between research and patient care, this web-based activity uses didactic presentations to apply evidence-based concepts in routine clinical care. The activity focuses on six different areas of oncology: breast cancer, gastrointestinal cancers, lung cancer, MDS/AML, NHL/CLL and multiple myeloma. These have been selected based on a number of factors including the overwhelming need for and interest of practicing oncologists in additional educational resources in these malignancies. By providing access to the latest research developments on the treatment of these significant tumor types in a single event, this activity will assist medical oncologists and hematologists in the formulation of up-to-date clinical management strategies.
TARGET AUDIENCE
This activity has been designed to meet the educational needs of medical, surgical and radiation oncologists and hematologists.
LEARNING OBJECTIVES
Upon completion of this activity, participants should be able to:
- Apply the results of emerging clinical trial data, including those presented at the 2009 ASCO annual meeting, to the evidence-based care of patients with breast, gastrointestinal, thoracic and hematologic cancers.
- Recall the design of ongoing trials in breast, gastrointestinal, thoracic and select types of hematologic cancer, and identify how they may impact existing treatment algorithms.
- Effectively integrate commercially available targeted monoclonal antibodies and tyrosine kinase inhibitors into the individualized management of common tumors.
- Summarize the findings from recent clinical trials designed to test the efficacy and safety of diverse combination chemotherapeutic and/or biologic approaches for patients with advanced-stage cancer.
- Utilize clinical risk factors, cytogenetics and other biomarkers to tailor therapy for patients with hematologic cancer.
- Counsel appropriately selected patients for participation in ongoing clinical trials evaluating novel agents and regimens for the treatment of cancer.
ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
Research To Practice designates this educational activity for a maximum of 2.75 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
HOW TO USE THIS CME ACTIVITY
This CME activity is a web-based video. To receive credit, the participant should review the Internet content and complete the Post-test and Educational Assessment and Credit Form located at
CME.ResearchToPractice.com.
CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
FACULTY — Dr Winer and Dr Wolff had no real or apparent conflicts of interest to disclose. The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr Kim — Advisory Committee: AstraZeneca Pharmaceuticals LP, Genentech BioOncology, ImClone Systems Incorporated, Lilly USA LLC, OSI Oncology, Sanofi-Aventis; Paid Research: AstraZeneca Pharmaceuticals LP, Genentech BioOncology, ImClone Systems Incorporated, Lilly USA LLC, OSI Oncology. Dr Ghobrial — Advisory Committee: Celgene Corporation, Novartis Pharmaceuticals Corporation; Speakers Bureau: Celgene Corporation, Millennium Pharmaceuticals Inc, Novartis Pharmaceuticals Corporation. Dr Kantarjian — Paid Research: Bristol-Myers Squibb Company, Genzyme Corporation, Novartis Pharmaceuticals Corporation. Dr Czuczman — Advisory Committee: Amgen Inc, Biogen Idec, Celgene Corporation, Cephalon Inc, Genentech BioOncology, GlaxoSmithKline, Lilly USA LLC, Millennium Pharmaceuticals Inc, Novartis Pharmaceuticals Corporation; Lectures: Biogen Idec, Genentech BioOncology.
MODERATOR — Neil Love: Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: Abraxis BioScience, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer Pharmaceuticals Corporation/Onyx Pharmaceuticals Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Centocor Ortho Biotech Services LLC, Cephalon Inc, Eisai Inc, EMD Serono Inc, Genentech BioOncology, Genomic Health Inc, Genzyme Corporation, GlaxoSmithKline, ImClone Systems Incorporated, Lilly USA LLC, Merck and Company Inc, Millennium Pharmaceuticals Inc, Monogram BioSciences Inc, Novartis Pharmaceuticals Corporation, OSI Oncology, Roche Laboratories Inc, Sanofi-Aventis and Wyeth.
RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.
This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
This program is supported by educational grants from AstraZeneca Pharmaceuticals LP, Celgene Corporation, Genentech BioOncology, Genomic Health Inc, Millennium Pharmaceuticals Inc and Sanofi-Aventis.
Hardware/Software Requirements:
An Internet connection that is at least 28.8 Kbps
A monitor set to 1280 x 1024 pixels or more
Netscape 7.x or newer, Internet Explorer 5.x or newer, or Firefox
Macromedia Flash plug-in 6.0 or greater
Adobe Acrobat Reader
(Optional) Sound card and speakers for audio
Last review date: December 2009
Expiration date: December 2010
